Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294775 | 0.91 | CTSS (0.52) | SYKIDO1SIGMAR1CA12CA1 | |
| SCHEMBL6428058 | 0.88 | ALOX5 (0.52) | SYKPPARG | |
| SCHEMBL1294752 | 0.86 | TDP1 (0.46) | SYKSIGMAR1PPARAPPARG | |
| SCHEMBL30806988 | 0.85 | CYP17A1 (0.51) | SYKSIGMAR1 | |
| SCHEMBL1295503 | 0.85 | CTSS (0.48) | CTSSCTSK | |
| SCHEMBL1294872 | 0.85 | GAA (0.54) | IDO1PPARAPPARG | |
| SCHEMBL1295442 | 0.85 | CTSS (0.48) | CTSSCTSK | |
| SCHEMBL1296370 | 0.85 | EPHX2 (0.46) | — | |
| SCHEMBL1295524 | 0.84 | POLB (0.49) | SYKIDO1SIGMAR1ATMGLS | |
| SCHEMBL1294826 | 0.84 | HTT (0.50) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925746-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2906581-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906582-A1 | MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014056748-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014056954-A1 | MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| EP-1981854-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1303488-A1 | PIPERIDINE COMPOUNDS FOR USE AS CCR-3 INHIBITORS | Novartis AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002004420-A1 | PIPERIDINE COUMPOUNDS FOR USE AS CCR-3 INHIBITORS | NOVARTIS AG (CH) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | SYK 1372/4885IDO1 520/4885SIGMAR1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.